A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Stanford University
Stanford University
National Cancer Institute (NCI)